Edition:
United Kingdom

Intersect ENT Inc (XENT.OQ)

XENT.OQ on NASDAQ Stock Exchange Global Market

32.75USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$32.75
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
60,047
52-wk High
$34.40
52-wk Low
$10.88

Chart for

About

Intersect ENT, Inc. is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology... (more)

Overall

Beta: --
Market Cap(Mil.): $894.66
Shares Outstanding(Mil.): 29.19
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.16 16.44
EPS (TTM): -- -- --
ROI: -- 14.01 10.62
ROE: -- 16.85 14.20

BRIEF-‍James Flynn​ reports 5.92 pct passive stake in Intersect ENT

* ‍James Flynn​ reports 5.92 percent passive stake in Intersect ENT as of Nov 6 - SEC filing Source text : (http://bit.ly/2jwmJXW) Further company coverage:

16 Nov 2017

BRIEF-FDA performs pre-approval inspection of Intersect ENT's menlo park facility

* FDA performs pre-approval inspection of Intersect ENT's menlo park facility

06 Nov 2017

BRIEF-Intersect ENT Inc reports Q3 revenue $22.3 million

* Intersect ENT Inc - ‍outlook for 2017 gross margin continues to be about 84%​

02 Nov 2017

BRIEF-Intersect ENT qtrly net loss per share $0.08

* Q2 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S

01 Aug 2017

Earnings vs. Estimates